Two-pronged, hypoglycemic "protective" heart, GLP-1RA weekly preparation effectively reduces insulin resistance in patients

*For medical professionals only

Smeglutide confronts multiple dilemmas and improves the prognosis

Innovative mechanisms of hypoglycemic drugs continue to emerge, opening up the possibility

Some GLP-1RA drugs, including smegglutide, have been jointly recommended

Professor Qin Jie shared a classic case, "In the year of the listing of smeglutide, there was a patient who impressed me, that is, a 36-year-old female diabetic patient who underwent hemodialysis treatment in the nephrology department of our hospital three times

"When patients are found to have severe insulin resistance, the risk of cardiovascular and cerebrovascular disease is very large, even if the patient has been undergoing hemodialysis three times a week to maintain kidney function, but this still does not reduce the risk

Professor Qin Jie said that the evidence-based medical research of GLP-1RA drugs has confirmed that it has good cardio-kidney benefits and reliable safety, and the patient is already undergoing regular hemodialysis treatment without worrying too much about drug toxicity and side effects

"Smeglutide has been used clinically for a whole year, in addition to showing good blood sugar control, it also has a great contribution to reducing the risk of cardiovascular disease in diabetic patients, so smeglutide is very popular

"The continuous emergence of new hypoglycemic drugs has also given doctors more 'weapons' to fight diseases

"In short, as a long-acting GLP-1RA, smegluotide not only has a significant hypoglycemic effect, but also takes into account the role of cardiovascular protection and improvement of blood lipid profile, and I believe that in the future, with the release of more evidence-based medical evidence and the more widely used clinical application, the advantages of smegglutide can be maximized to benefit the majority of diabetic groups
.
" Resources:

Cui Jiale, Yang Yan, Peng Yaming, et al.
Progress in the application of GLP-1RA in type 2 diabetes[J].
Medical Review,2021,27(4):6.

[2] EINARSON T R,ACS A,LUDWIG C,et al.
Prevalence of cardiovascular disease in type 2 diabetes:a systematic literature review of scientific evidence from across the world in 2007-2017[J].
Cardiovasc Diabetol,2018,17(1):83.

[3] LU J,HE J,LI M,et al.
Predictive Value of Fasting Glucose,Postload Glucose,and Hemoglobin A(1c)on Risk of Diabetes and Complications in Chinese Adults[J].
Diabetes Care,2019,42(8):1539-48.

Wang Fujun,Wang Wenqi.
Interpretation of China's Guidelines for the Prevention and Treatment of Type 2 Diabetes (2020 Edition)[J].
Journal of Hebei Medical University,2021,42(12):1365-71.

[5] ASSOCIATION A D.
Standards of Medical Care in Diabetes—2021 Abridged for Primary Care Providers[J].
Clinical Diabetes,2021,39(1):14-43.

[6] DUAN J,WANG C,LIU D,et al.
Prevalence and risk factors of chronic kidney disease and diabetic kidney disease in Chinese rural residents:a cross-sectional survey[J].
Sci Rep,2019,9(1):10408.

[7] Marbury TC,Flint A,Jacobsen JB,Derving Karsbøl J,Lasseter K.
Pharmacokinetics and Tolerability of a Single Dose of Semaglutide,a Human Glucagon-Like Peptide-1 Analog,in Subjects With and Without Renal Impairment.
Clin Pharmacokinet.
2017; 56(11):1381-1390.

Semeglutide instructions.

[9] MARSO S P,BAIN S C,CONSOLI A,et al.
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes[J].
N Engl J Med,2016,375(19):1834-44.

-End-

"This article is only used to provide scientific information to healthcare professionals and does not represent the position of the platform"